Evaluating therapeutic candidates for their efficacy requires tools that can perform rapid quantitative measurement of multiple biological readouts along with the ability to analyze large data sets and provide actionable insights. In this webinar two scientists will share how they used the Intellicyt® iQue Screener Plus platform to advance their research.
- What BH3 profiling is and how it works
- How BH3 profiling can be used to screen for chemosensitivity
- How simultaneous evaluation of T-cell activation and cytokine secretion provides valuable insights for optimizing adoptive cell therapy development
Jeremy Ryan, S.M.
Staff Scientist, Letai Lab
Dana-Farber Cancer Institute
Jeremy received his bachelors in chemistry and biology from St. Mary’s College of Maryland and his masters in chemistry at MIT. He joined the Letai lab in 2006 where he has been involved in many projects, including the development of BH3 profiling from Dr. Letai’s original ELISA system into the kit-format cytometry methods currently used today.
John O’Rourke, Ph.D.
Manager of Assay Development
Intellicyt, A Sartorius Company
John O’Rourke completed his Ph.D. in Biochemistry from The Ohio State University where he studied cancer biology and gene regulation. During his postdoctoral training at Nationwide’s Children’s Research Institute and the University of New Mexico, he continued his studies in cancer biology along with the development of viral and nanoparticle-based therapeutics. Dr. O’Rourke completed his MBA at the Andersen School of Management at the University of New Mexico and joined IntelliCyt in 2017. Dr. O’Rourke is currently the Manager of Assay Development at Intellicyt.